Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


Last 266.75 GBp
Change Today -15.50 / -5.49%
Volume 303.2K
GWP On Other Exchanges
Symbol
Exchange
London
OTC US
NASDAQ GM
Frankfurt
NASDAQ GM
Stuttgart
As of 11:35 AM 02/5/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Sovereign House

Vision Park

Chivers Way

Histon

Cambridge, CB24 9BZ

United Kingdom

Phone: 44 1223 266 800

Fax: 44 1223 235 667

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing and commercializing therapeutics from proprietary cannabinoid product platform in a range of disease areas. The company’s primary cannabinoid product candidate is Epidiolex, a liquid formulation of pure plant-derived cannabidiol (CBD), which is in development for the treatment of various rare pediatric epilepsy disorders. The company is planning to commercialize Epidiolex in the United States and elsewhere using its own sales and marketing organization. The company received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), for Epidiolex for the treatment of both Dravet syndrome and Lennox-Gastaut syndrome (LGS), each of which are severe infantile-onset, genetic, drug-resistant epilepsy syndromes. The company has commenced four pivotal Phase 3 trials of Epidiolex, two in Dravet syndrome and two in LGS, each of which is due to report top-line results in 2016. The company’s strategy for the development of Epidiolex within the field of pediatric epilepsy is to initially concentrate formal development efforts on three orphan indications: Dravet Syndrome, LGS and Tuberous Sclerosis Complex. The company received Orphan Drug Designation from the U.S. FDA for Epidiolex for the treatment of both Dravet syndrome and LGS. Additionally, the company has received Fast Track Designation from the FDA and Orphan Designation from the European Medicines Agency (EMA) for Epidiolex for the treatment of Dravet syndrome. Dravet syndrome is a severe infantile-onset, genetic, drug-resistant epilepsy syndrome with a distinctive but complex electroclinical presentation. In April 2015, the company commenced an additional Phase 3 trial in Dravet syndrome. LGS is a type of epilepsy with multiple types of seizures, particularly tonic (stiffening) and atonic (drop) seizures. In May 2015, the company commenced the Phase 3 pivotal trials program for Epidiolex in LGS. Tuberous Sclerosis Complex is a genetic disorder that causes non-malignant tumors to form in many different organs, primarily in the brain, eyes, heart, kidney, skin and lungs. In addition to Epidiolex, the company’s epilepsy product candidates also include GWP42006, which features CBDV as the primary cannabinoid. The company completed a Phase 1 trial of GWP42006. The company is evaluating a combination product containing GWP42002:GWP42003 in the treatment of recurrent glioblastoma multiforme (GBM), a particularly aggressive brain tumor, which is considered a rare disease by the FDA and the EMA. The company received Orphan Drug Designation from the FDA for GWP 42002:GWP42003 combination for the treatment of GBM. The company completed recruitment of the 20 patient placebo-controlled 2a phase of the trial, and top-line data is expected around mid-2016. In April 2015, the company received Orphan Drug Designation from the FDA for CBD for the treatment of NHIE. In July 2015, the company received Orphan Drug Designation from the EMA for CBD for the treatment of perinatal asphyxia. In addition, in July 2015, the company received Fast Track Designation from the FDA. Trademarks Sativex and Epidiolex are registered trademarks of the company. Intellectual Property The company’s patent portfolio related to the use of CBD and/or Cannabidivarin (CBDV) includes 14 patent families containing 1 or more pending and/or issued patents with claims in the treatment of epilepsy, compositions, extraction techniques, CBD and CBDV extracts and highly purified plant-derived CBD. The company has a patent granted in the U.K., which claims the use of CBD in combination with certain standard anti-epileptic drugs in the treatment of epilepsy. It also had a patent granted in the U.K. in October 2015, which claims the use of CBD in combination with certain standard anti-epileptic drugs in the treatment of epilepsy. The company’s intellectual property portfolio, as of September 30, 2015, included 60 patent families with issued and/or pending claims directed to plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery and the therapeutic uses of

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GWP:LN 266.75 GBp -15.50

GWP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cannabis Science Inc $0.01 USD +0.001
Medical Marijuana Inc $0.04 USD -0.0014
PharmaCyte Biotech Inc $0.06 USD -0.001
View Industry Companies
 

Industry Analysis

GWP

Industry Average

Valuation GWP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.8x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact GW PHARMACEUTICALS PLC, please visit www.gwpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.